TY - JOUR T1 - Assessment of COVID-19 risk and prevention effectiveness among spectators of mass gathering events JF - medRxiv DO - 10.1101/2021.07.05.21259882 SP - 2021.07.05.21259882 AU - Tetsuo Yasutaka AU - Michio Murakami AU - Yuichi Iwasaki AU - Wataru Naito AU - Masaki Onishi AU - Tsukasa Fujita AU - Seiya Imoto Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/06/2021.07.05.21259882.abstract N2 - There is a need to evaluate and minimise the risk of novel coronavirus infections at mass gathering events, such as sports. In particular, to consider how to hold mass gathering events, it is important to clarify how the local infection prevalence, the number of spectators, the capacity proportion, and the implementation of preventions affect the infection risk. In this study, we used an environmental exposure model to analyse the relationship between infection risk and infection prevalence, the number of spectators, and the capacity proportion at mass gathering events in football and baseball games. In addition to assessing risk reduction through the implementation of various preventive measures, we assessed how face-mask-wearing proportion affects infection risk. Furthermore, the model was applied to estimate the number of infectors who entered the stadium and the number of newly infected individuals, and to compare them with actual reported cases. The model analysis revealed an 86%–95% reduction in the infection risk due to the implementation of face-mask wearing and hand washing. Among the individual measures, face-mask wearing was particularly effective, and the infection risk increased as the face-mask-wearing proportion decreased. A linear relationship was observed between infection risk at mass gathering events and the infection prevalence. Furthermore, the number of newly infected individuals was also dependent on the number of spectators and the capacity proportion independent of the infection prevalence, confirming the importance of considering spectator capacity in infection risk management. These results highlight that it is beneficial for organisers to ensure prevention compliance and to mitigate or limit the number of spectators according to the prevalence of local infection. Both the estimated and reported numbers of newly infected individuals after the events were small, below 10 per 3–4 million spectators, despite a small gap between these numbers.Competing Interest StatementW.N. received financial support from the Kao Corporation until March 2020 in context outside the submitted work. T.Y., M.O., and W.N. have received financial support from the Kao Corporation for collaborative research project in context of measures at mass gathering events. T.Y., M.O., and W.N. have received financial support from Yomiuri Giants, Japan Professional Football League, and Japan Professional Basketball League. M.M., T.Y., M.O., N.S., W.N, and S.I. attend the new coronavirus countermeasures liaison council jointly established by the Nippon Professional Baseball Organization and Japan Professional Football League as experts without any rewards. T.Y., M.O., and W.N. are advisors to the Japan National Stadium. Other authors declare no competing interests. The findings and conclusions of this article are solely the responsibility of the authors and do not represent the official views of any institution.Funding StatementAll data can be found in the text. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable and not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data can be found in the text. ER -